SUMMARY We have studied the inheritance of four cloned DNA sequences which recognise restriction fragment length polymorphisms on the short arm of the X chromosome in families with Becker and Duchenne muscular dystrophy. We have confirmed linkage of two probe loci to the disease loci and have combined our results with those previously published to give a maximum lod score of 11 642 at a recombination fraction of 0.15 for DXS41 (probe 99-6), and a maximum lod of 15-84 at a recombination fraction of 0*15 for DXS84 (probe 754). Linkage of these diseases to the loci defined by the pERT87 probes and probe pXJ1 .1 has also been studied, giving maximum lod scores of 8-634 and 5*118 at recombination fractions of 0-02 and 0-00 respectively. The information obtained using these polymorphic DNA 
Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are X linked recessive muscle disorders. DMD is more common and more severe than BMD, with an incidence of approximately 1 in 3000 to 3500' newborn males, compared to approximately 1 in 30 000 for BMD. They are clinically similar in the pattern of muscle involvement, but BMD follows a more benign course.
The localisation of DMD on the X chromosome initially came from the study of several girls who manifested the clinical signs of muscular dystrophy and who were all found to have X;autosome translocations, with a common breakpoint at Xp2l. both DMD and BMD,14 15 and by the fact that two of the girls with X;autosome translocations involving Xp2l have had relatively mild diseases, more compatible with a diagnosis of Becker than Duchenne muscular dystrophy. 16 17 In order to increase their usefulness in clinical situations, the linkage of polymorphic loci to the disease loci must be studied in pedigrees. We have investigated the linkage of four polymorphic loci defined by probes 99-6 (DXS4J18), pERT87 (DXS164'9), 754 shown in  table 2 for DMD, table 3 for BMD, and table 4 for the combined DMD and BMD families (the maximum lod scores are also shown in these tables). We have presented the data for the loci defined for the three pERT87 probes separately and have also presented combined data for the DXS164 locus.
Discussion
The data presented confirm genetic linkage between The precise location of the closer DNA sequences relative to the disease locus is not known. Hybridisation of these cloned DNA sequences to somatic cell hybrids containing the translocated chromosomes from female patients suffering from BMD and DMD show that the breakpoints of the X chromosome, although cytologically visible at Xp2l, do vary, and that some are distal to pXJ1-1 and pERT 87, while others are proximal. 27 The breakpoints all lead to manifestations of the disease, suggesting that both loci are within the region functionally related to muscular dystrophy.
Although locus DXS164 shows deletions in affected boys, it has been reported to show recombination at about 5%. 5 We have found one crossover between DXS164 and the disease locus (family D6 in the appendix). Our data show a maximum lod score of 8-634 at 0=0-02, supporting the use of a recombination fraction of about 5% for genetic counselling purposes. These two loci are, therefore, closer than any of the previously published linked loci, and so will give a more accurate figure for carrier risks and in prenatal diagnosis. The heterozygote frequencies of the pERT probes indicate that 95% of women will be heterozygous for at least one polymorphic site. In families where the affected boy shows a deletion of a pERT or pXJ1 1 DNA sequence, the appropriate probe can often be used to give even more accurate counselling, particularly where prenatal diagnosis is required, since the disease causing mutation is effectively being probed directly.
Prenatal diagnosis is best undertaken when the expectant mother is heterozygous for DNA probes which define loci flanking the disease locus. 8 The risk of error then becomes the risk of a double recombinational event, which is very low. Unfortunately, the pERT probes and pXJ1-1 cannot currently be used as flanking markers, in conjunction with other probes, as their precise location relative to the disease locus is not known and may, indeed, vary from family to family. It is, therefore, important to test women with more loosely linked DNA probes as well, to try and establish heterozygous flanking markers. For calculating carrier risks, the pedigree and CK data must also be taken into account.
It is important that the linkage between the disease locus and loci newly defined by DNA probes is constantly reviewed, so that up to date figures can be used in calculating carrier risks and enabling prenatal diagnosis to be carried out more accurately in families at risk for Duchenne and Becker muscular dystrophy.
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